Skip to main content


Ref-Nr: TA-TA04632


The technology relates to an antibody for the treatment of candidiasis that is able to block/mask CaHgt1p and thereby enhance phagocytosis of candida. This represents a completely novel way of fungal treatment.


Candida is a leading pathogen in the opportunistic fungal infection, particularly among immunocompromised and hospitalized patients. Systemic candidiasis refers to infection of the visceral organs. It is a life-threatening infection, usually involving multiple organs, the Candida having spread via the bloodstream to organs such as the liver, spleen and kidney.

The incidence of candidemia has been increasing due to a variety of factors, including immunosuppression, increasingly invasive technologies, and the use of broad-spectrum antibiotics. Invasive candidiasis accounted for 17% of hospital-acquired infections reported during the European Study on the Prevalence of Nosocomial Infections in Critically Ill patients (EPIC), US data have shown that Candida species are the fourth most common cause of bloodstream infection, accounting for 8 to 15% of all nosocomial bloodstream infections. Incidence rate of invasive candidiasis varies considerably and has been estimated to affect 0.2– 1.0 in 10,000 persons per year (Ref: European Medicines Agency Evaluation of Medicines for Human Use).


The innate immunity plays a crucial role in antifungal defense. The complement system is a key machinery of the innate immunity, recognizing and killing various pathogens, including Candida. Glucose transporter CaHgt1p is a surface protein from Candida that functions as complement inhibitor. CaHgt1p can bind complement regulator Factor H (FH) thus interfering with complement activation and phagocytosis of Candida molecule by human neutrophils. The technology presented here relates to an antibody that is able to block/mask CaHgt1p, thereby enhancing phagocytosis - this represents a completely novel way of fungal treatment.


The use of anti-CaHgt1 antibodies for Candida treatment could be of special benefit for prolonged Candidiasis medication and treatment of Candida strains resistant to systemic antifungal agents. This antibody has been generated and tested in vitro.

Dr. David Lederbauer
+43 512 507-34403
Universität Innsbruck; ICT-Technologiepark, Technikerstraße 21a
6020 Innsbruck




  • EP anhängig
  • PCT anhängig


Antifungal, Candidiasis

Kontakt | Geschäftsstelle

TechnologieAllianz e. V.
Christiane Bach-Kaienburg

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr